Twist Bioscience Collaborating With Eli Lilly's TuneLab to Accelerate Antibody Drug Discovery
MT newswire2026/09/16 12:40
08:40 AM EDT, 09/16/2026 (MT Newswires) -- Twist Bioscience (TWST) said Wednesday it has agreed to provide antibody characterization data services to Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly (LLY). Under the agreement, TuneLab users can order Twist antibody services using preferred protocols to generate data for AI-enabled drug discovery models, including Lilly's AbLab antibody developability prediction model, the company said. Twist said the arrangement will connect experimental data with AI models and support more efficient selection of antibody candidates. Financial terms of the collaboration were not disclosed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.